Meta-analysis application to hERG safety evaluation in clinical trials

被引:0
|
作者
Zhao, Xutong [1 ]
Sun, Jing [1 ]
Huang, Dalong [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Biometr 6, Off Biostat, Silver Spring, MD 20993 USA
关键词
Concentration-QTc model; cardiac safety assessment; meta-analysis; safety margin; thorough QT study; THOROUGH QT/QTC; PROLONG; QTC;
D O I
10.1080/10543406.2024.2365972
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
One objective of meta-analysis, which synthesizes evidence across multiple studies, is to assess the consistency and investigate the heterogeneity across studies. In this project, we performed a meta-analysis on moxifloxacin (positive control in QT assessment studies) data to characterize the exposure-response relationship and determine the safety margin associated with 10-msec QTc effects for moxifloxacin based on 26 thorough QT studies submitted to the FDA. Multiple meta-analysis methods were used (including two novel methods) to evaluate the exposure-response relationship and estimate the critical concentration and the corresponding confidence interval of moxifloxacin associated with a 10-msec QTc effect based on the concentration-QTc models. These meta-analysis methods (aggregate data vs. individual participant data; fixed effect vs. random effect) were compared in terms of their precision and robustness. With the selected meta-analysis method, we demonstrated the homogeneity and heterogeneity of the moxifloxacin concentration-QTc relationship in studies. We also estimated the critical concentration of moxifloxacin that can be used to calculate the hERG safety margin of this drug.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Evaluation of Cumulative Meta-analysis of Rare Events as a Tool for Clinical Trials Safety Monitoring
    Siontis, George C. M.
    Nikolakopoulou, Adriani
    Efthimiou, Orestis
    Raeber, Lorenz
    Windecker, Stephan
    Juni, Peter
    JAMA NETWORK OPEN, 2020, 3 (09)
  • [2] Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
    Monami, M.
    Genovese, S.
    Mannucci, E.
    DIABETES OBESITY & METABOLISM, 2013, 15 (10): : 938 - 953
  • [3] THE EFFICACY AND SAFETY OF VERNAKALANT - A META-ANALYSIS OF RANDOMISED CLINICAL TRIALS
    Chin, A.
    Velasco, A.
    Guzman, J.
    Morillo, C. A.
    CANADIAN JOURNAL OF CARDIOLOGY, 2012, 28 (05) : S322 - S323
  • [4] Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials
    Qian Shi
    Daniel J. Sargent
    International Journal of Clinical Oncology, 2009, 14 : 102 - 111
  • [5] Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials
    Shi, Qian
    Sargent, Daniel J.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (02) : 102 - 111
  • [6] Safety meta-analysis of clinical trials delivering TTFields to the upper torso
    Ceresoli, G. L.
    Pless, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 73 - 73
  • [7] The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials
    Bajtel, Akos
    Kiss, Tivadar
    Toth, Barbara
    Kiss, Szabolcs
    Hegyi, Peter
    Vorhendi, Nora
    Csupor-Loffler, Boglarka
    Gede, Noemi
    Hohmann, Judit
    Csupor, Dezso
    PHARMACEUTICALS, 2022, 15 (01)
  • [8] Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
    Polyzos, Konstantinos A.
    Mavros, Michael N.
    Vardakas, Konstantinos Z.
    Makris, Marinos C.
    Rafailidis, Petros I.
    Falagas, Matthew E.
    PLOS ONE, 2012, 7 (08):
  • [9] Meta-analysis of clinical trials of Permixon
    Lowe, F
    Robertson, C
    Roehrborn, C
    Boyle, P
    JOURNAL OF UROLOGY, 1998, 159 (05): : 257 - 257
  • [10] Meta-analysis of clinical trials of ribomunyl
    Boyle, P
    Robertson, C
    PEDIATRIC RESEARCH, 1999, 45 (05) : 749 - 749